Abstract
Objectives To estimate the proportion and correlates of self-reported financial difficulty among patients with multiple myeloma (MM) or chronic lymphocytic leukemia (CLL).
Setting 23 U.S. community and minority oncology practice sites affiliated with the National Cancer Institute Community Oncology Research Program (NCORP).
Participants 521 patients (≥18 years) with MM or CLL were consented and 416 responded to a survey (completion rate=79.8%). Respondents had a MM diagnosis (74.0%), an associate degree or higher (53.4%), were White (89.2%), insured (100%) and treated with clinician-administered drugs (68.0%).
Interventions Observational, prospective, protocol-based survey administered in 2019-2020.
Primary and secondary outcome measures Financial difficulty was assessed using a single-item standard measure, the EORTC QLQC30: “Has your physical condition or medical treatment caused you financial difficulties in the past year?” and using an ‘any-or-none’ composite measure of 22 items assessing financial difficulty, worries and the use of cost-coping strategies. Multivariable logistic regression models assessed the association between financial difficulty, diagnosis, and socioeconomic and treatment characteristics.
Results 16.8% reported experiencing financial difficulty using the single-item measure and 60.3% using the composite measure. Most frequently endorsed items in the composite measure were financial worry about having to pay large medical bills related to cancer and difficulty paying medical bills. Financial difficulty using the single-item measure was associated with having MM versus CLL (adjusted odds ratio [aOR], 0.34; 95% CI, 0.13-0.84; P=.02), having insurance other than Medicare (aOR, 2.53; 95% CI, 1.37-4.66; P=.003), being non-White (aOR, 2.21; 95% CI, 1.04-4.72; P=.04), and having a high school education or below (aOR, 0.36; 95% CI, 0.21-0.64; P=.001). Financial difficulty using the composite measure was associated with having a high school education or below (aOR, 0.62; 95% CI, 0.41-0.94; P=.03).
Conclusions U.S. patients with blood cancer report financial difficulty, especially those with low socio-economic status. Evidence-based and targeted interventions are needed.
Strengths
NCORP, a program of the National Cancer Institute (NCI), is a national network for cancer clinical trials and care delivery studies that is comprised of 7 research bases and 46 community sites across the U.S., 14 of which are designated as Minority/Underserved community sites. The study had strong engagement and participation across diverse NCORP Sites across the country and their affiliates. Strong site engagement resulted in high patient recruitment and retention rates for this study (79.8%), despite coincident timing with the initial stages of the COVID-19 pandemic.
The survey tool was composed of previously validated items that were modified for this population and new questions that were evaluated for comprehension, which facilitates comparison of our findings to others previously published. Patients targeted for recruitment were treated in the community and recruitment aimed to represent the socioeconomic characteristics of the prevalent patient population. The study relied on both self-report and medical chart abstraction to establish key dependent and independent variables.
The primary outcome variable was a previously developed, and empirically tested measure, supporting study internal and external validity. We also used a secondary composite measure of financial difficulty to present a more holistic picture of how cancer diagnosis and treatment impact patients’ daily lives and inform decisions to delay or forego care and use cost-coping strategies. By capturing specific worries, decisions and strategies, the composite measure indicates areas where there is a need for greater patient engagement and resource provision at the site of care.
Limitations
Among 105 participants who were not included in the final sample, the majority (n=66) were excluded from analysis because they could not be contacted within the 8-week period due to unexpectedly high recruitment volumes across sites.
While NCORP sites from across the country participated in the study, 60% of patients recruited to the study were from the Midwest. Although this is the most representative study of financial difficulty in U.S. blood cancer patients to date, our findings may not be fully generalizable to the national CLL and MM communities due to these limitations.
Competing Interest Statement
Conti reports research support from the National Science Foundation, the National Cancer Institute, the National Institute on Drug Abuse, the Veterans Administration, the Leukemia and Lymphoma Society, the Sloan Foundation and Arnold Ventures and consulting fees from Greylock McKinnon Associates unrelated to this manuscript. All other authors declare no conflicts of interest to disclose.
Clinical Protocols
https://clinicaltrials.gov/study/NCT03870633
Funding Statement
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), UG1CA189816, UG1CA189859, UG1CA233180, UG1CA233270, UG1CA233277, UG1CA233329, UG1CA233373, The Leukemia & Lymphoma Society and the American Cancer Society RSGI-16-163-01-CPHPS. This research was also made possible by philanthropic support to The Leukemia & Lymphoma Society from AbbVie Inc.; Amgen, Inc.; Genentech, Inc. & Biogen; Merck & Company, Inc.; Pfizer Inc.; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech; Takeda Oncology and Walgreens. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor any sponsor.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NCI/Alliance Central IRB gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study will be available by request through Alliance/NCI.
